...
首页> 外文期刊>Cancer Management and Research >Screening and Identification of Potential Biomarkers for Hepatocellular Carcinoma: An Analysis of TCGA Database and Clinical Validation
【24h】

Screening and Identification of Potential Biomarkers for Hepatocellular Carcinoma: An Analysis of TCGA Database and Clinical Validation

机译:肝细胞癌潜在生物标志物的筛选和鉴定:TCGA数据库分析及临床验证

获取原文
           

摘要

Introduction: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Up to now, many genes associated with HCC have not yet been identified. In this study, we screened the HCC-related genes through the integrated analysis of the TCGA database, of which the potential biomarkers were also further validated by clinical specimens. The discovery of potential biomarkers for HCC provides more opportunities for diagnostic indicators or gene-targeted therapies. Methods: Cancer-related genes in The Cancer Genome Atlas (TCGA) HCC database were screened by a random forest (RF) classifier based on the RF algorithm. Proteins encoded by the candidate genes and other associated proteins obtained via protein–protein interaction (PPI) analysis were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The newly identified genes were further validated in the HCC cell lines and clinical tissue specimens by Western blotting, immunofluorescence, and immunohistochemistry (IHC). Survival analysis verified the clinical value of genes. Results: Ten genes with the best feature importance in the RF classifier were screened as candidate genes. By comprehensive analysis of PPI, GO and KEGG, these genes were confirmed to be closely related to HCC tumors. Representative NOX4 and FLVCR1 were selected for further validation by biochemical analysis which showed upregulation in both cancer cell lines and clinical tumor tissues. High expression of NOX4 or FLVCR1 in cancer cells predicts low survival. Conclusion: Herein, we report that NOX4 and FLVCR1 are promising biomarkers for HCC that may be used as diagnostic indicators or therapeutic targets.
机译:简介:肝细胞癌(HCC)是世界上最常见的癌症。到目前为止,尚未确定与HCC相关的许多基因。在这项研究中,我们通过TCGA数据库的综合分析筛选了HCC相关基因,其中临床标本也进一步验证了潜在的生物标志物。对HCC的潜在生物标志物的发现提供了更多的诊断指标或基因靶向疗法的机会。方法:通过基于RF算法的随机林(RF)分类器筛选癌症基因组Atlas(TCGA)HCC数据库中的癌症相关基因。经过蛋白质 - 蛋白质相互作用(PPI)分析所获得的候选基因和其他相关蛋白质编码的蛋白质进行基因本体(GO)和基因或基因组(Kegg)途径富集分析的基因本体学(GO)和Kyoto百科全书。通过蛋白质印迹,免疫荧光和免疫组织化学(IHC),在HCC细胞系和临床组织标本中进一步验证了新鉴定的基因。存活分析验证了基因的临床价值。结果:射击RF分类剂中最佳特征重要性的10个基因被筛选为候选基因。通过对PPI的综合分析,GO和KEGG,这些基因被证实与HCC肿瘤密切相关。选择代表性的NOx4和FLVCR1以通过生化分析进一步验证,所述生物化学分析显示在癌细胞系和临床肿瘤组织中的上调。癌细胞中NOx4或FLVCR1的高表达预测生存率低。结论:本文报告说,NOX4和FLVCR1对HCC的有前途的生物标志物,其可用作诊断指示剂或治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号